References
- World Health Organization. Coronavirus disease (COVID-19) pandemic. [cited 2020 May 7]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- World Health Organization. Global report on psoriasis. [cited 2020 May 7]. Available from: https://www.who.int/publications-detail/global-report-on-psoriasis
- Ciuluvica C, Fulcheri M, Amerio P. Expressive suppression and negative affect, pathways of emotional dysregulation in psoriasis patients. Front Psychol. 2019;10:1907.
- Rigas HM, Bucur S, Ciurduc DM, et al. Psychological stress and depression in psoriasis patients – a dermatologist’s perspective. Maedica (Buchar). 2019;14(3):287–291.
- Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010;23(2):174–180.
- Devrimci-Ozguven H, Kundakci TN, Kumbasar H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14(4):267–271.
- De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–1682.
- Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog Treat. 2020;31(4):317–318.
- Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio. 2013;4(3):e00165–e00113.
- Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
- Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667–1670.
- Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools [published online ahead of print, 2020 Mar 3]. Virol Sin. 2020;1–6.
- Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. [cited 2020 May 10]. Available from: https://www.researchgate.net/publication/339642124
- Ma W-T, Yao X-T, Peng Q, et al. The protective and pathogenic roles of IL-17 in viral infections: friend or foe? Open Biol. 2019;9(7):190109.
- Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21(3):307–305.
- A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19). [cited 2020 May 25]. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=50251
- A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). [cited 2020 May 25]. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49889
- Burlando M, Carmisciano L, Cozzani E, et al. A survey of psoriasis patients on biologics during COVID-19: a single centre experience. [published online ahead of print, 2020 May 25]. J Dermatol Treat. 2020;1–3.
- Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. [published online ahead of print, 2020 May 1]. Dermatol Ther. 2020;e13475.
- Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–2205.
- Gisondi P, Facheris P, Dapavo P, et al. The impact of COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. [published online ahead of print, 2020 Apr 28]. Br J Dermatol. 2020. DOI:https://doi.org/10.1111/bjd.19158.
- Megna M, Ruggiero A, Marasca C, et al. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328–329.
- International League of Dermatological Societies. Guidance on the use of systemic therapy for patients with psoriasis/atopic dermatitis during the Covid-19 (Sars-Cov-2, Coronavirus) pandemic. [cited 2020 April]. Available from: https://ilds.org/covid-19/guidance-psoriasis-atopic- dermatitis/
- American Academy of Dermatology (AAD). Guidance on the use of biologic agents during COVID-19 outbreak. Available from: https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/07b614658aff5fc6ccc 4c0bd910509a3/Biologics_and_COVID_19_FINAL_V2.pdf
- Jones DS. History in a crisis – lessons for Covid-19. N Engl J Med. 2020;382(18):1681–1683.